Posts by muellerdesign
Venture, Grants and Funds Announcements
Mass General Brigham Ventures Current Stats $450 Million Capital Under Management 48 Portfolio Companies 15 Exits $148 Million Realized & Publicly Traded Announcements Verve Therapeutics completes $306.7 million IPO We are pleased to announce that Verve Therapeutics completed its initial public offering (NASDAQ: VERV). The company upsized its offering by 2.2 million shares and…
Read MoreNew Initiative Seeks to Enhance Diversity, Equity and Inclusion in the Innovation Process
The Nobel prize-winning American chemist Linus Pauling once said, “If you want to have good ideas, you must have many ideas.” Generating more ideas for new drugs, devices and therapeutics; increasing the diversity of researchers participating in the innovation process; and helping more patients are key goals of the new Innovator Community Expansion Initiative (ICEI)…
Read MoreBrigham Ignite: The Spark that Catalyzes Innovation
BWH announced Brigham Ignite, a program designed to kindle and advance discoveries with clinical commercial potential through both expertise and funding. Read more
Read MoreRebuilding the Brain in Parkinson’s Disease
Gene and cell therapy at a crossroads After glimpsing the promise of gene and cell therapy, Mass General Brigham researchers are now enhancing the technology to drive new treatments for rare and common diseases Replacing defective genes or cells with healthy ones has been a goal of modern medicine for decades. And while that aspiration…
Read More‘Moving the Needle’ for Glioblastoma
Gene and cell therapy at a crossroads After glimpsing the promise of gene and cell therapy, Mass General Brigham researchers are now enhancing the technology to drive new treatments for rare and common diseases Replacing defective genes or cells with healthy ones has been a goal of modern medicine for decades. And while that aspiration…
Read MoreToward Gene Therapies for Hearing Loss
Gene and cell therapy at a crossroads After glimpsing the promise of gene and cell therapy, Mass General Brigham researchers are now enhancing the technology to drive new treatments for rare and common diseases Replacing defective genes or cells with healthy ones has been a goal of modern medicine for decades. And while that aspiration…
Read MoreDriven to Solve Devastating Rare Diseases
Gene and cell therapy at a crossroads After glimpsing the promise of gene and cell therapy, Mass General Brigham researchers are now enhancing the technology to drive new treatments for rare and common diseases Replacing defective genes or cells with healthy ones has been a goal of modern medicine for decades. And while that aspiration…
Read More2021 WMIF Panels: Illustrated
For each 2021 World Medical Innovation panel over the course of three days, visual drawings were made to encapsulate what was discussed in an illustrative way. To view, download them all here.
Read More2021 Disruptive Dozen
The three-day forum concluded with the introduction of the Disruptive Dozen—12 new technologies identified by senior leaders from Mass General Brigham as having the chance to significantly improve healthcare in the next two years. #12 | New Gene and Cell Therapies to Fight a Formidable Brain Cancer Glioblastoma is the most common type of brain…
Read More2021 Innovation Discovery Grants (IDG) Awarded
Thursday afternoon highlights also included the awarding of six Innovation Discovery Grants (IDG) to Mass General Brigham investigators working on gene and cell therapy (GCT) advancements. Each award winner will receive $100,000 toward ongoing development and future commercialization, based on the potential to improve health outcomes, meet articulated milestones, and attract follow-on investment as assessed…
Read More2021 World Medical Innovation Forum | Day 3 Recap
Day 3 of the World Medical Innovation Forum codified the challenges of bringing new gene and cell therapies to market—shared across treatment strategies, delivery systems and disease areas. Priority needs included more reliable and repeatable manufacturing processes, building resiliency into the supply chain, and working with regulators to develop more streamlined pathways to approval. Venture…
Read More2021 World Medical Innovation Forum | Day 2 Recap
Day Two of the World Medical Innovation Forum took a deeper dive into the potential of GCT therapeutics to treat different diseases—from ultra-rare genetic disorders to highly prevalent chronic diseases such as diabetes. Discussions touched on different strategies for modifying genes and delivering therapies, as well as opportunities for using lessons learned from last year’s…
Read More